TIDMORPH

RNS Number : 1942K

Open Orphan PLC

04 May 2022

Open Orphan plc

("Open Orphan" or the "Company")

Comment re: speculation

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes market speculation regarding a potential delisting. The Company confirms that it has no plans to delist and is working with Liberum to complete their due diligence following their appointment as Nominated Adviser to the Company. It looks forward to confirming the completion of the required due diligence in due course.

The wording included in the announcement dated 28 April 2022 announcing the appointment of Liberum as Nominated Adviser was standard wording for all former clients of Arden Partners given the relatively short notice provided to the Company to appoint and complete take-on of a new Nominated Adviser following the recommended takeover of Arden Partners by The Ince Group plc.

For further information please contact:

 
 Open Orphan plc                                                        +353 (0) 1 644 0007 
 Cathal Friel, Executive Chairman 
 Yamin Khan, Chief Executive Officer 
 
 Liberum Capital (Nominated Adviser 
  and Joint Broker)                                                    +44 (0) 20 3100 2000 
 Ben Cryer/ Edward Mansfield/ Phil 
  Walker/ Will King 
 
 finnCap plc (Joint Broker)                                            +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson / Richard 
  Chambers 
 
 Davy (Euronext Growth Adviser and 
  Joint Broker)                                                         +353 (0) 1 679 6363 
 Anthony Farrell 
 
 Walbrook PR (Financial PR & IR)           +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
  Paul McManus / Sam Allen / Louis                   +44 (0)7980 541 893 / +44 (0) 7502 558 
  Ashe-Jepson                                                                         258 / 
                                                                        +44 (0) 7747 515393

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of new models, such as malaria and COVID-19, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.

Open Orphan runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion(R) platform, this unique dataset includes clinical, immunological, virological, and digital (wearable) biomarkers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPUMAAUPPGRW

(END) Dow Jones Newswires

May 04, 2022 02:01 ET (06:01 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Hvivo Charts.
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Hvivo Charts.